


COLORECTAL CANCER EARLY DETECTION TEST REPORT



Spot early signs of
colorectal cancer, by
analyzing DNA shed by
cancer cells (ctDNA).



Scan QR code for more
information



PATIENT INFORMATION

PERSONAL INFORMATION		SAMPLE INFORMATION		TEST INFORMATION	
Full Name:	Sample Patient	Sample Type:	Blood	Ordering Physician:	DR. GS
NRIC/Passport/ID:	XXXXXX	Date Collected:	01/01/2025	MCR/MMC no.:	XXXXXX
Gender:	Female	Date Received by Lab:	02/01/2025	Sample Collection Place:	Sample Hospital
Date of Birth:	19/01/1987			Date Reported:	20/01/2025


CLINICAL INFORMATION

Remark: An in-depth analysis and commentary on a clinical topic, supported by the latest evidence and insights. Clinical comments can also include personal experiences.

RESULT

LABCODE ID: SAAAAAR29 | ECD ID: ECDXXX01 | PERFORMED TEST: SPOT-MAS CRC

RISK ASSESSMENT



ctDNA Z-Score

Scope of Investigation

ctDNA Z-Score

Risk Value

1

Result

No Abnormalities Detected

• Negative Score: ≤3
• Positive Score: >3

ctDNA (circulating tumor DNA) is DNA released from cancerous cells and tumors, circulating freely in the bloodstream.

What Your Result Means:

No signals have been found to suggest the possibility that you are having cancer in the colorectum.

This result is only valid on the received sample


NOTE:

- A negative result (no ctDNA signal detected) does **NOT COMPLETELY** rule out the presence of a tumor because the tumor is out of scope (colorectum) OR is located in a difficult location for ctDNA release⁽¹⁾, OR the **secondary cancer** has a radically different omics from the primary cancer⁽²⁾.
- The sensitivity of the test is 81.0%⁽³⁾, which means that for **every 100 colorectal cancer cases, about 19 cases will be missed**.
- Recommend using this test as a supporting screening test, **NOT** as a substitute for recommended routine cancer screening tests.
- You should continue regular health check-ups and cancer screenings as directed by your doctor.

(1) Bettgowda, Chetan et al. "Detection of circulating tumor DNA in early- and late-stage human malignancies." *Science translational medicine* 6.224 (2014). doi:10.1126/scitranslmed.3007094

(2) Hao, Xiaoke et al. "DNA methylation markers for diagnosis and prognosis of common cancers." *Proceeding of the National Academy of Sciences* 114.28 (2017). doi:10.1073/pnas.1703577114

(3) Gene Solutions internal validation data on colorectal cancer



SAMPLE REPORT

This report is electronically signed by

Laboratory Director

Christopher Wong, PhD

Gene Solutions Singapore

5 Tai Seng Avenue #02-54, Singapore 536671
 MOH license: L/2411577/CLB/001/242

YOUR RESULT

EARLY CANCER SCREENING BASED ON DNA RELEASED FROM TUMOR (ctDNA)

- This analysis helps detect Colorectal cancer based on the ctDNA released from the tumor (ctDNA). These DNA fragments can be released early, when the tumor is small, has not metastasized and has not caused the typical clinical manifestations of cancer. The content of ctDNA is directly proportional to tumor size and metastasis, while ctDNA release capacity depends on cancer type and tumor locations, which will affect the ability to detect ctDNA in blood.
- This ctDNA analysis result shows that **ctDNA SIGNAL (DNA from tumor) originating from the colorectum was NOT DETECTED** in your blood sample.

Note:

- This result shows that after analyzing your blood sample, **NO signal suggestive of Colorectal cancer was detected.**
- This analysis screening for cancer at the time blood sample was drawn and does NOT rule out the cancer risk in the future. With a negative result, you should repeat this test annually for early cancer screening AND in combination with recommended routine cancer screening tests to increase the chance of detecting cancer at early stage.
- This test is a supporting test, **NOT** a substitute for current routine cancer screening and diagnostic tests such as colonoscopy, abdomen CT scan, biopsy-histopathology.

With this test result, we recommend that you take the following additional steps:

1 You need to periodically monitor your health every year and go to a doctor when there are signs of unwellness or early warning signs of cancer appear (note below), in order to have a diagnosis and suitable treatment.

Note: Delaying medical examination when there are suspicious symptoms will lead to the risk of diagnosing cancer at a late stage.

7 Warning Signs Of Cancer

The American Cancer Society has recommended some warning signs of cancer. To make it easier to remember, experts use the initials C-A-U-T-I-O-N (warning), including:

- C (Change in bowel or bladder habits): Change in bowel and bladder habits. For example: frequent urination, hematuria, diarrhea, constipation, diarrhea with alternating constipation, bloody stools...
- A (A sore that does not heal): Persistent pain that does not relieve. Any chronic, persistent, or unexplained pain is a sign of concern.
- U (Unusual bleeding or discharge): Unusual bleeding or discharge from the nose, mouth, urinary tract, digestive tract or vagina.
- T (Thickening or lump in the breast or elsewhere): A thickening or lump in the breast or any other part of the body.
- I (Indigestion or difficulty swallowing): Indigestion or difficulty swallowing.
- O (Obvious change in size, color, shape, or thickness of a wart, mole, or mouth sore): An obvious change in the size, color, shape or thickness of a wart, mole, or sore in mouth.
- N (Nagging cough or hoarseness): Persistent cough or hoarseness.

Note: When one of the above symptoms is present without an obvious cause, persists for more than 2 weeks and/or tumor DNA (ctDNA) analysis is positive, it is most likely a sign of cancer. You should see a specialist for advice.

2 You need to build a healthy diet, work, exercise and rest to maintain physical and mental health. Maintaining a healthy lifestyle also helps reduce the risk of cancer, specifically as follows:


- Limit your exposure to UV rays by avoiding excessive direct sun exposure
- Any new, unusual or other moles should be reported to your doctor
- Avoid or limit smoking
- Exercise regularly
- Limit the use of alcoholic beverages
- Maintain a healthy weight
- Eat lots of fruits and vegetables
- Gain insight into your personal health and your family's medical history

If you have any questions or need more consultation about the results, please contact Gene Solutions customer service through your physician.

ctDNA SCREENING METHOD

How SPOT-MAS™ test works

1



Cancer cells grow and form a tumor

2



Tumor cells release DNA fragments into the bloodstream, known as circulating tumor DNA (ctDNA)

3



Obtain 01 tube of whole blood (10ml). Extract cell-free DNA from Plasma.

4

Analyze Genetic, Epigenetic, and Fragmentomic Features of ctDNA

5




No ctDNA detected: SPOT-MAS test looked for a cancer signal and did not find one at this moment.



ctDNA detected: SPOT-MAS test detected the presence of ctDNA, indicating presence of cancer cells.

Apply next-generation sequencing to analyze multiple features of ctDNA



Use AI-guided model to predict the tissue of origin of the detected ctDNA.

TECHNICAL SPECIFICATION

SPOT-MAS TECHNOLOGY

Cell-free DNA is extracted from the blood sample and processed using a proprietary next-generation sequencing (NGS) workflow, which includes both whole genome sequencing and amplicon-based sequencing. Sequencing is performed using DNA nanoball technology on the DNBSEQ-G400 system (MGI Tech Co.). The resulting data are then analyzed using AI-guided machine learning models to detect the presence of ctDNA in the blood and identify the tumor origin, based on a multi-omic database that incorporates genetic, epigenetic, and fragmentomic features of cfDNA.

LABORATORY INFORMATION

- This screening test was developed by, and its performance characteristics determined by Gene Solutions Genomics Pte Ltd, a company registered in Singapore.
- Gene Solutions Genomics is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (License no. L/24I1577/CLB/001/242) under the Healthcare Services Act 2020.

PUBLICATIONS

1. Nguyen, T. H. H., Lu, Y. T., Le, V. H., Bui, V. Q., Nguyen, L. H., Pham, N. H., ... & Tran, L. S. (2023). Clinical validation of a ctDNA-based assay for multi-cancer detection: An interim report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 participants. *Cancer Investigation*, 41(3), 232-248.
2. Nguyen, V. C., Nguyen, T. H., Phan, T. H., Tran, T. H. T., Pham, T. T. T., Ho, T. D., ... & Tran, L. S. (2023). Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma. *BMC cancer*, 23(1), 1-17.
3. Nguyen, H. T., Khoa Huynh, L. A., Nguyen, T. V., Tran, D. H., Thu Tran, T. T., Khang Le, N. D., ... & Tran, L. S. (2022). Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer. *Future Oncology*, 18(35), 3895-3912.
4. Pham, T. M. Q., Phan, T. H., Jasmine, T. X., Tran, T. T. T., Huynh, L. A. K., Vo, T. L., ... & Tran, L. S. (2023). Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer. *Frontiers in Oncology*, 13, 1950.
5. Nguyen, H. T., Luong, B. A., Tran, D. H., Nguyen, T. H., Ngo, Q. D., Le, L. G. H., ... & Tran, D. T. (2022). Ultra-deep sequencing of plasma-circulating DNA for the detection of tumor-derived mutations in patients with nonmetastatic colorectal cancer. *Cancer Investigation*, 40(4), 354-365.
6. Nguyen, H. N., Cao, N. P. T., Van Nguyen, T. C., Le, K. N. D., Nguyen, D. T., Nguyen, Q. T. T., ... & Tran, L. S. (2021). Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations. *Scientific Reports*, 11(1), 16436.
7. Tran, L. S., Nguyen, Q. T. T., Nguyen, C. V., Tran, V. U., Nguyen, T. H. T., Le, H. T., ... & Giang, H. (2020). Ultra-deep massive parallel sequencing of plasma cell-free DNA enables large-scale profiling of driver mutations in Vietnamese patients with advanced non-small cell lung cancer. *Frontiers in Oncology*, 10, 1351.
8. Dang, A. T. H., Tran, V. U., Tran, T. T., Thi Pham, H. A., Le, D. T., Nguyen, L., ... & Giang, H. (2020). Actionable mutation profiles of non-small cell lung cancer patients from Vietnamese population. *Scientific reports*, 10(1), 1-11.
9. Nguyen, H. T., Tran, D. H., Ngo, Q. D., Pham, H. A. T., Tran, T. T., Tran, V. U., ... & Nguyen, H. N. (2020). Evaluation of a liquid biopsy protocol using ultra-deep massive parallel sequencing for detecting and quantifying circulation tumor DNA in colorectal cancer patients. *Cancer Investigation*, 38(2), 85-93.
10. Tran, L. S., Pham, H. A. T., Tran, V. U., Tran, T. T., Dang, A. T. H., Le, D. T., ... & Nguyen, H. N. (2019). Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. *PloS one*, 14(12), e0226193
11. Pham, T.M.Q., Phan, T.H., Jasmine, T.X., Tran, T.T.T., Huynh, L.A.K., Vo,... & Tran, L.S. (2023). Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer. *Front. Oncol.* 13, 1127086.
12. Nguyen, V.T.C., Nguyen, T.H., Doan, N.N.T., Pham, T.M.Q., Nguyen, G.T.H., Nguyen, Thanh Dat, Tran, T.T.T., Vo, D.L.,... & Tran, L.S. (2023). Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. *eLife* 12, RP89083.
13. Nguyen, T.H.H., Lu, Y.-T., Le, V.H., Bui, V.Q., Nguyen, L.H., Pham, N.H.,... & Tran, L.S. (2023). Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants. *Cancer Investigation* 41, 232–248.
13. Doan, N. N. T., Nguyen, T. H., Tran, T. H., Nguyen, T. H. H., Nguyen, V. T. C., Giang, H., Tran, L. S., & Phan, M. D. (2024). Tissue of origin detection for cancer tumor using low-depth cfDNA samples through combination of tumor-specific methylation atlas and genome-wide methylation density in graph convolutional neural networks. *Journal of Clinical Oncology*, 42(23_suppl), 224. https://doi.org/10.1200/jco.2024.42.23_suppl.224
14. Nguyen, L. H. D., Tieu, B. L., Nguyen, T. T., Ha, N. P., Nguyen, G. T. H., Nguyen, T. H. H., Le, V. H., Bui, V. Q., Nguyen, L. H., Pham, N. H., Phan, T. H., Nguyen, H. T., Tran, V. S., Bui, C. V., Vo, V. K., Nguyen, P. T. N., Dang, H. H. P., Pham, V. D., Cao, V. T., ... Nguyen, D. S. (2024). A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study. *Future Science OA*, 10(1). <https://doi.org/10.1080/20565623.2024.2395244>.
15. Van Thien Nguyen, C., Nguyen, T. H. H., Vo, D. H., Van, T. T. V., Nguyen, G. T. H., Tran, T. H., Huynh, L. A. K., Nguyen, T. D., Tran, N., Ha, T. M. T., Le, P. T. Q., Truong, X. L., Nguyen, H. L., Tran, U. V., Hoang, T. Q., Nguyen, V. B., Le, V. C., Nguyen, X. C., ... Tran, L. S. (2024). Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests. *Future Oncology*, 1–11. <https://doi.org/10.1080/14796694.2024.2413266>

Share the awareness of early
cancer detection today.
Early detection is the key to
save lives.



www.genesolutions.com

Our Labs & Offices

Singapore

Tower C, Tai Seng Exchange 5 Tai Seng Avenue, #02-54
Singapore 536671

Indonesia

Menara Tendean (MTen) 11th Floor, Unit 11.10, Jl. Kapten
Tendean No. 20C, Mampang Prapatan, Jakarta Selatan, DKI
Jakarta, 12710

Malaysia

Common Ground, G.016, Jaya One, The Square, 72A, Jln
Profesor Diraja Ungku Aziz, Seksyen 13, 46200 Petaling Jaya,
Selangor, Malaysia

Philippines

ENC5 306-307, 3rd Floor Mother Ignacia Corner Samar St.
South Triangle, Quezon City, Philippines.

Thailand

26/40 12th Floor, Orakarn Building, Chidlom Road,
Lumpini, Patumwan, Bangkok 10330 Thailand

Vietnam

186-188 Nguyen Duy Duong, Ward 2, District 10, Ho Chi Minh City,
740500 Viet Nam

